Since ERα represents the main regulator of estrogensin breast tissue and is one of the principal targets for breast cancertreatment, its negative regulation mediated by PARP7 could be beneficialin this kind of cancer.154 On the contrary,the downregulation of INF-I response in which PARP7 is involved couldbe responsible for a reduced T-cell-mediated antitumor activity.155 Thus, PARP7 could represent an immunotherapeutictarget, and through its inhibition, anticancer activity can be achieved. This evidence concerns the gene TIPARP and cancer.